第99.1展示文本
personalis报告2024年第二季度财务结果
由生物制药业务带动，年度营业收入强劲增长35%，其中生物制药业务增长117%。
提高2024年全年营业收入指引
加利福尼亚州弗里蒙特 - 2024年8月7日 - Personalis, Inc.（纳斯达克：PSNL），一家在精准肿瘤基因组学领域领先的公司，今天公布了截至2024年6月30日的第二季度财务业绩，并介绍了最近的业务成就。
最近的业务成就
与2023年第二季度相比，2024年第二季度的结果
1
营业收入增长反映出客户对我们的技术和平台的信心不断增强。重要的是，我们临床测试成交量的增长意味着我们可以看到对患者生活的影响。现在，我们的合作伙伴已经提出了令人信服的NeXt Personal临床证据，我们期待利用这一点来获取Medicare报销，并显著增加我们可以帮助的患者人数。”首席执行官克里斯·霍尔表示：“随着我们继续执行我们的Win-in-MRD策略，我们对自己推动广泛采用患者检测的能力比以往任何时候都更有信心。”
2024年第三季度和修订后的全年展望
personalis期望2024年第三季度如下：
personalis预计在2024年整年会有以下表现：
网络广播和电话会议信息
personalis将在2024年8月7日周三美国太平洋时间下午2点（东部时间下午5点）收盘后举行电话会议，讨论2024年第二季度的财务业绩，以及2024年的计划。请拨打800-717-1738（国内用户）或646-307-1865（国际用户）参与直播。直播网络研讨会可在 https://investors.personalis.com。电话会议结束后不久将提供网络研讨会的回放，并将存档在公司网站上。
关于Personalis公司。
在personalis，我们通过突破性的个性化测试改变癌症的积极管理。我们的目标是推动癌症管理的新范式，从活检到患者的一生。我们的高度敏感的检测结合肿瘤和正常的基因组特征分析，配合专有算法，提供先进的见解
2
癌症在不断进化的同时。我们的产品旨在检测最小残留疾病（MRD）和早期复发，根据超全面的基因组分析进行靶向治疗选择，并加强药物开发的生物标志物策略。Personalis总部位于加利福尼亚弗里蒙特。要了解更多，请访问 www.personalis.com并通过LinkedIn和X (推特).
非通用会计准则财务指标
为了补充我们根据GAAP制定的财务指导，我们提供了截至2024年12月31日全年预期的非GAAP净损失，其中不包括来自于向Tempus发行的未行使权证所产生的收入和费用。我们排除了与Tempus发行的未行使权证公允价值相关的收入和费用，因为这些是非现金财务指标，需要根据截至每个报告日期的本公司普通股的当时交易价格进行公允价值重估，因此在预测Tempus权证在未来测量日期的公允价值时存在重大不确定性。基于这个原因，我们没有提供我们前瞻性的非GAAP净损失与GAAP净损失（最直接可比的GAAP财务指标）的调和，依赖于适用法规中规定的“不合理费力”的例外情况。
前瞻性声明
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical facts and can generally be identified by terms such as “anticipate,” “estimate,” “expect,” “if,” “may,” “future,” “will” or similar expressions. These statements include statements relating to: Personalis’ third quarter and full year 2024 outlook for revenue, non-GAAP net loss, and cash usage, the attributes, advantages or clinical validity of the NeXT Personal Dx test, broad adoption of the NeXT Personal Dx test for patient testing and the benefits to patients from use of the same, and Personalis’ obtaining Medicare coverage. Such forward-looking statements involve known and unknown risks and uncertainties and other factors that may cause actual results to differ materially from any anticipated results or expectations expressed or implied by such statements, including the risks, uncertainties and other factors that relate to the timing and pace of new orders from customers, including from Natera and the U.S. Department of Veterans Affairs Million Veterans Program; the timing of tissue, blood, and other specimen sample receipts from customers, which can materially impact revenue quarter-over-quarter and year-over-year; Personalis’ ability to demonstrate attributes, advantages or clinical validity of the NeXT Personal Dx test, the rate of adoption of the NeXT Personal Dx test, Personalis’ ability to obtain Medicare coverage and reimbursement, Personalis’ achievement of milestones set forth in the collaboration and co-commercialization agreement with Tempus, the success of Personalis’ clinical sales team and Tempus’ sales and marketing efforts, the expected benefits or success of Personalis’ relationships with research collaborators, the impact of Personalis’ abstract presentations at the American Society of Clinical Oncology medical conference in May, and the adoption and use of the NeXT Personal Dx test by oncologists. These and other potential risks and uncertainties that could cause actual results to differ materially from the results predicted in these forward-looking statements are described under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Personalis’ Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Securities and Exchange Commission (SEC) on February 28, 2024, as updated by Personalis’ Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, filed with the SEC on May 8, 2024, and Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, being filed with the SEC today. All information provided in this release is as of the date of this press release, and any forward-looking statements contained herein are based on assumptions that we believe to be reasonable as of this date. Undue reliance should not be placed on the forward-looking statements in this press release, which are based on information available to us on the date hereof. Personalis undertakes no duty to update this information unless required by law.
3
Contacts:
Investor Relations Contact:
Caroline Corner
investors@personalis.com
646-277-1279
Media:
pr@personalis.com
4
PERSONALIS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)
(in thousands, except share and per share data)
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
||||||||||
|
|
2024 |
|
|
2023 |
|
|
2024 |
|
|
2023 |
|
||||
Revenue |
|
$ |
22,580 |
|
|
$ |
16,699 |
|
|
$ |
42,105 |
|
|
$ |
35,559 |
|
Costs and expenses |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Cost of revenue |
|
|
14,543 |
|
|
|
11,907 |
|
|
|
28,575 |
|
|
|
26,037 |
|
Research and development |
|
|
12,957 |
|
|
|
17,852 |
|
|
|
25,728 |
|
|
|
34,425 |
|
Selling, general and administrative |
|
|
11,973 |
|
|
|
12,134 |
|
|
|
23,575 |
|
|
|
26,231 |
|
Restructuring and other charges |
|
|
— |
|
|
|
152 |
|
|
|
— |
|
|
|
4,037 |
|
Total costs and expenses |
|
|
39,473 |
|
|
|
42,045 |
|
|
|
77,878 |
|
|
|
90,730 |
|
Loss from operations |
|
|
(16,893 |
) |
|
|
(25,346 |
) |
|
|
(35,773 |
) |
|
|
(55,171 |
) |
Interest income |
|
|
1,136 |
|
|
|
1,465 |
|
|
|
2,495 |
|
|
|
2,718 |
|
Interest expense |
|
|
(9 |
) |
|
|
(39 |
) |
|
|
(18 |
) |
|
|
(86 |
) |
Other income (expense), net |
|
|
2,968 |
|
|
|
1 |
|
|
|
7,537 |
|
|
|
(25 |
) |
Loss before income taxes |
|
|
(12,798 |
) |
|
|
(23,919 |
) |
|
|
(25,759 |
) |
|
|
(52,564 |
) |
Provision for income taxes |
|
|
4 |
|
|
|
36 |
|
|
|
11 |
|
|
|
50 |
|
Net loss |
|
$ |
(12,802 |
) |
|
$ |
(23,955 |
) |
|
$ |
(25,770 |
) |
|
$ |
(52,614 |
) |
Net loss per share, basic and diluted |
|
$ |
(0.24 |
) |
|
$ |
(0.50 |
) |
|
$ |
(0.50 |
) |
|
$ |
(1.11 |
) |
Weighted-average shares outstanding, basic and diluted |
|
|
52,394,678 |
|
|
|
47,669,513 |
|
|
|
51,536,632 |
|
|
|
47,204,891 |
|
5
PERSONALIS, INC.
SUPPLEMENTAL REVENUE INFORMATION (unaudited)
(in thousands)
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
||||||||||
|
|
2024 |
|
|
2023 |
|
|
2024 |
|
|
2023 |
|
||||
Pharma tests and services |
|
$ |
13,197 |
|
|
$ |
6,083 |
|
|
$ |
23,009 |
|
|
$ |
12,416 |
|
Enterprise sales |
|
|
7,958 |
|
|
|
7,386 |
|
|
|
15,930 |
|
|
|
16,844 |
|
Population sequencing |
|
|
1,280 |
|
|
|
3,000 |
|
|
|
2,780 |
|
|
|
6,005 |
|
Other |
|
|
145 |
|
|
|
230 |
|
|
|
386 |
|
|
|
294 |
|
Total revenue |
|
$ |
22,580 |
|
|
$ |
16,699 |
|
|
$ |
42,105 |
|
|
$ |
35,559 |
|
6
PERSONALIS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited)
(in thousands, except share and per share data)
|
|
June 30, 2024 |
|
|
December 31, 2023 |
|
||
Assets |
|
|
|
|
|
|
||
Current assets |
|
|
|
|
|
|
||
Cash and cash equivalents |
|
$ |
47,747 |
|
|
$ |
56,984 |
|
Short-term investments |
|
|
39,225 |
|
|
|
57,195 |
|
Accounts receivable, net |
|
|
12,921 |
|
|
|
17,730 |
|
Inventory and other deferred costs |
|
|
9,164 |
|
|
|
10,474 |
|
Prepaid expenses and other current assets |
|
|
4,046 |
|
|
|
4,361 |
|
Total current assets |
|
|
113,103 |
|
|
|
146,744 |
|
Property and equipment, net |
|
|
52,662 |
|
|
|
57,366 |
|
Operating lease right-of-use assets |
|
|
17,166 |
|
|
|
17,852 |
|
Other long-term assets |
|
|
2,571 |
|
|
|
3,137 |
|
Total assets |
|
$ |
185,502 |
|
|
$ |
225,099 |
|
Liabilities and Stockholders’ Equity |
|
|
|
|
|
|
||
Current liabilities |
|
|
|
|
|
|
||
Accounts payable |
|
$ |
9,936 |
|
|
$ |
14,920 |
|
Accrued and other current liabilities |
|
|
19,248 |
|
|
|
23,941 |
|
Contract liabilities |
|
|
4,174 |
|
|
|
3,288 |
|
Short-term warrant liability |
|
|
775 |
|
|
|
5,085 |
|
Total current liabilities |
|
|
34,133 |
|
|
|
47,234 |
|
Long-term operating lease liabilities |
|
|
36,524 |
|
|
|
38,321 |
|
Long-term warrant liability |
|
|
1,513 |
|
|
|
4,942 |
|
Other long-term liabilities |
|
|
1,060 |
|
|
|
5,161 |
|
Total liabilities |
|
|
73,230 |
|
|
|
95,658 |
|
Commitments and contingencies |
|
|
|
|
|
|
||
Stockholders’ equity |
|
|
|
|
|
|
||
Preferred stock, $0.0001 par value — 10,000,000 shares authorized; none issued |
|
|
— |
|
|
|
— |
|
Common stock, $0.0001 par value — 200,000,000 shares authorized; 53,052,847 and 50,480,694 shares issued and outstanding, respectively |
|
|
5 |
|
|
|
5 |
|
Additional paid-in capital |
|
|
606,863 |
|
|
|
598,364 |
|
Accumulated other comprehensive loss |
|
|
(120 |
) |
|
|
(222 |
) |
Accumulated deficit |
|
|
(494,476 |
) |
|
|
(468,706 |
) |
Total stockholders’ equity |
|
|
112,272 |
|
|
|
129,441 |
|
Total liabilities and stockholders’ equity |
|
$ |
185,502 |
|
|
$ |
225,099 |
|
7